菲利普莫里斯国际公司正向美国食品和药物管理局（FDA）的一个顾问委员会发出强烈呼吁，希望该委员会能建议监管机构将旗下产品Zyn授权为“改良风险烟草产品”。这一举措旨在基于科学证据，推动对尼古丁袋装产品的公共卫生效益进行正式认可。
菲利普莫里斯国际公司正向美国食品和药物管理局（FDA）的一个顾问委员会发出强烈呼吁，希望该委员会能建议监管机构将旗下产品Zyn授权为“改良风险烟草产品”。这一举措旨在基于科学证据，推动对尼古丁袋装产品的公共卫生效益进行正式认可。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.